• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services


  • Print
  • Share
  • E-mail

Norvir (ritonavir oral solution) August 2008

Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) -- August 2008


The detailed view includes drug products with safety labeling changes to the BOXED WARNING, CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, or PATIENT PACKAGE INSERT/MEDICATION GUIDE sections. Deletions or editorial revisions made to these sections are not included in this summary. Read about the new physician labeling format.

Summary View

Sections Modified


  • PR Interval Prolongation
  • Information for Patients
    • Patients should be informed that Norvir may produce changes in the electrocardiogram (eg, PR prolongation)...


  • Postmarketing Experience
    • Cardiovascular System
      • First–degree AV block, second-degree AV block, third-degree AV block, right bundle branch block have been reported (See PRECAUTIONS – PR Interval Prolongation).


  • What Are the Possible Side Effects of Norvir?
    • Changes in the electrocardiogram (EKG)...